Ah.. it would have been better if they did it when their stock price wasn't trading in the single digits (like the previous secondary). we'll find out soon enough what the last qtr's cash burn was, but i feel that Lim and co. pulled the trigger in cash raising a bit prematurely, all things being equal. This is heavy dilution for those of us who aren't buying more currently.
Doc, the recent pipeline prioritization was unquestionably due to their unexpected high cash burn. Their op expenses seem to be higher than their comp group. Lim seems to be spending a lot on exec salaries and building a top-heavy mgmt structure. Mgmt does seem to believe in RXDX 101 hence the recent insider buying. Can't tell at this pt if it is better than, let's say, LOXO lead product which is also a TRK-targeted inhibitor - this has a 50%- response rate but LOXO has 2x mkt cap.
So why hasn't it? it sounds like you work for the co. RXDX provides more info, to the public, seems to be further along in its trials, and has more cash on-hand than any of its comps - MRTX, BPMC and LOXO, yet it trades at a severe discount and has the smallest mkt cap. Why the Disrespect?